<DOC>
	<DOCNO>NCT01593475</DOCNO>
	<brief_summary>This phase II trial choose induction chemotherapy gemcitabine cisplatin follow Chemoradiotherapy ( CRT ) gemcitabine optimize treatment pancreas cancer patient locally advanced disease purpose trial evaluate efficacy induction CT gemcitabine cisplatin follow CRT unresectable pancreatic carcinoma .</brief_summary>
	<brief_title>Induction Chemotherapy With Gemcitabine Cisplatin Followed CCRT Unresectable Pancreatic Carcinoma</brief_title>
	<detailed_description>The primary endpoint feasibility compliance induction chemotherapy gemcitabine cisplatin follow CRT locally advance unresectable pancreatic cancer . Previous study show approximately 20 % patient locally advanced disease develop early distant metastasis . [ 6 , 7 ] Thus , expect least 80 % total patient eligible induction chemotherapy completion induction chemotherapy . An experimental arm result compliance 80 % would merit study . If true compliance rate patient eligible CRT ≤ 60 % , null hypothesis reject power 80 % type I error 5 % . Thus , require number evaluable patient 24 . Considering 10 % follow-up loss 20 % distant metastasis rate induction chemotherapy , total 34 eligible patient enrol .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Pathologically confirm adenocarcinoma pancreas Unresectable locally advanced disease base institutional standard criterion unresectability disease follow radical surgery . There evidence metastatic disease major viscera peritoneal seed Patients biliary gastroduodenal obstruction must drainage prior start chemoradiation All malignant disease must encompassable within single irradiation field ( 15x15cm maximum ) All patient must radiographically assessable disease No previous irradiation plan field Age ≥ 18 year performance status 0 1 Eastern Cooperative Oncology Group ( ECOG ) score Required Entry Laboratory Parameters WBC count ≥ 1,000/mm3 ; hemoglobin level ≥ 7.5 g/dL ; platelet count ≥ 100,000/mm3 ; total bilirubin ≤ 3.0 mg/dL ( Patients elevate bilirubin due obstruction stented bilirubin decrease ≤ 3.0 mg/dL prior study entry ) ; creatinine ≤ 3.0 mg/dL Oral intake ( include Jtube feeding ) ≥ 1,500 calories/day maintain . Signed informed consent form prior study entry There evidence metastasis major viscera peritoneal seed . Age &lt; 18 year Previous history RT adjacent plan field Poor performance status 2 4 Eastern Cooperative Oncology Group ( ECOG ) score Pregnant breast feeding status Previous history uncontrolled malignancy within 2 year</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>